8-K filing — BeyondSpring Inc. (BYSI)
Filed: 2026-10-06 AccNo: 0001171843-26-006465 Size: 362 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits
Stocks · News reference
BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BeyondSpring shares are trading lower. The company announced the FDA has granted Fast Track designation to Plinabulin and docetaxel for advanced non-small cell lung cancer.
BeyondSpring Says FDA Granted Fast Track To Plinabulin Plus Docetaxel In Lung Cancer; Agrees To Sell Majority Of China Unit To Biolin, Which Will Fund China Phase 3 Enrollment